Compare Bristol-Myers Squibb Co (BMY) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Visa Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Visa Inc trades at $356.02 (market cap $677.06B). The key difference: Visa Inc is far larger — about 5.8× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | V | |
|---|---|---|
Market Cap | $116.30B | $677.06B |
Sector | Health | Financials |
52-Week High | $62.37 | $362.13 |
52-Week Low | $42.60 | $295.52 |
Enterprise Value | $152.24B | $687.65B |
Dividend Yield | 4.42% | 0.75% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Visa (V) trades at $357.75, up 2.52% today, with a bullish technical signal and strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue grew to $40.0 billion in 2025, and net income margin remains robust at 51.68%. The stock is near its pivot point of $357, with support at $354 and resistance at $360. Analysts maintain a strong buy consensus, with an average price target of $394.50.
The outlook for Visa is positive, driven by earnings momentum and strategic initiatives like AI-powered commerce tools. However, risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a buy and institutional holdings increasing, the stock offers growth potential but requires monitoring of payment industry disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
